A Randomized Trial of Radical Radiotherapy for the Management of pT1G3 NXM0 Transitional Cell Carcinoma of the Bladder
Authors:
- S.J. HarlandSHS.J. Harland
- National Cancer Research Institute Bladder Clinical Studies GroupNGNational Cancer Research Institute Bladder Clinical Studies Group
- 1 September 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 178 (3) , 807-813
Abstract
We conducted a multicenter randomized trial in the United Kingdom to determine the efficacy of radical radiotherapy in reducing the incidence of progression of pT1G3 transitional cell carcinoma of the bladder to muscle invasive disease and subsequent disease fatality. Patients with a new diagnosis of pT1G3 NXM0 transitional cell carcinoma with unifocal disease and no carcinoma in situ (group 1), or with multifocal disease and/or carcinoma in situ (group 2) were eligible for the trial. Patients in group 1 were randomized between observation and radiotherapy to the bladder, and in group 2 between intravesical therapy and radiotherapy. From September 1991 to February 2003 a total of 210 patients from 37 centers in the United Kingdom were entered into the study. There were 77 patients in group 1 and 133 patients in group 2, and 6 patients were excluded from analysis because they were found to have pT2 disease by the reference pathologist. No evidence of an advantage with radiotherapy was found in terms of progression-free interval (hazard ratio 1.07; 95% CI 0.65, 1.74; p = 0.785), progression-free survival (hazard ratio 1.35; 95% CI 0.92, 1.98; p = 0.133) or overall survival (hazard ratio 1.32; 95% CI 0.86, 2.04; p = 0.193). To our knowledge this is the largest randomized trial performed in patients with pT1G3 disease for which 210 patients were recruited during 11 years. There is no evidence that radiotherapy is better than more conservative treatment. The prognosis of this group of patients appears to be poor irrespective of treatment and new treatment strategies need to be investigated.Keywords
This publication has 13 references indexed in Scilit:
- A Second Look at the pT1 G3 Bladder TumourClinical Oncology, 2005
- The role of repeat transurethral resection in the management of high‐risk superficial transitional cell bladder cancerBJU International, 2005
- A Retrospective Analysis of 153 Patients Treated With or Without Intravesical Bacillus Calmette-Guerin for Primary Stage T1 Grade 3 Bladder Cancer: Recurrence, Progression and SurvivalJournal of Urology, 2003
- Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and ToxicityJournal of Urology, 2003
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002
- The Fate of G3pT1 Bladder CancerBritish Journal of Urology, 1989
- A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.Journal of Clinical Oncology, 1987
- Stage T1, Grade 3 Transitional Cell Carcinoma of the Bladder: An Unfavorable Tumor?Journal of Urology, 1987
- Treatment of Superficial (T1) Tumours of the Bladder by Radical RadiotherapyBritish Journal of Urology, 1986
- Prognostic factors in local surgical treatment of invasive bladder cancer, with special reference to the presence of urothelial dysplasiaCancer, 1983